Tech Review has an article on Oxford Nanopore Technologies, one of the newest next-gen sequencing companies to enter the race for the $1000 genome. Because nanopore sequencing can analyze individual strands of DNA, the process saves time and money on sample prep. "We think we're the only label-free technology out there," Gordon Sanghera says. "There's no labeling. There's no amplification.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.